Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daclizumab in Wegener's Granulomatosis
NCT00040248Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jun 2002
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of daclizumab in granulomatosis with polyangiitis (GPA), sponsored by National Institute of Allergy and Infectious Diseases. Started Jun 2002; status: completed.
02
Drugs
daclizumab
03
Conditions
granulomatosis with polyangiitis (GPA)
Beyond the preview
Go deeper on NCT00040248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00040248.